Malvern Instruments Establishes New Biopharmaceutical Applications Laboratory
News Jul 31, 2015
The new laboratory will enable customers and Malvern applications specialists alike to experience and use Malvern’s range of specialist biophysical characterization systems in a working biopharmaceutical environment.
The new applications lab has been developed in partnership with Sevion Therapeutics, a San Diego based biopharmaceutical company that discovers, develops and acquires next-generation biologics. Sevion Therapeutics will host the laboratory for which Malvern will provide analytical instrumentation, training and continuing support. The lab came on stream in May 2015.
“As evidenced by the work of our Bioscience Development Initiative team, Malvern is absolutely committed to providing cutting edge analytical instrumentation that meets the needs of the biopharmaceutical industry,” said Paul Davies, Global Business Manager at Malvern Instruments. “We work very closely with all parts of the pharmaceutical industry but the highly dynamic nature of biopharmaceutical development and the rapid pace of change make it imperative that we have a fully functioning applications laboratory in an environment where there is access to real-world protein formulations and where our instruments sit within the workflow of a commercial enterprise. I am absolutely delighted that Sevion Therapeutics is our partner in this venture.”
Under the terms of the agreement, several different Malvern analyzers will be installed in the applications laboratory. Initially this will include two microcalorimeters - the new MicroCal PEAQ-ITC and a MicroCal VP-Capillary DSC; a Viscotek TDAmax multi-detector size exclusion chromatography system; and a Zetasizer Nano ZSP for the measurement of size, electrophoretic mobility of proteins, zeta potential of nanoparticles and surfaces, and optionally the microrheology of protein and polymer solutions. Further protein characterization technologies from Malvern’s portfolio will be installed at future dates.
Dr Jim Graziano, Chief Technology Officer at Sevion Therapeutics is very pleased to be working with Malvern. “This venture provides a great opportunity for Sevion Therapeutics to access the latest biophysical measurement techniques and to help shape future developments. Malvern will provide extensive training and continuing support to our teams, and we will benefit both from having extended access to high value instrumentation and from Malvern’s technology and applications expertise. We’re especially excited to be adding differential scanning calorimetry to our armory and to being among the first to use the new MicroCal PEAQ-ITC system.”
MicroCal PEAQ-ITC is the recently launched, new-generation isothermal titration calorimeter (ITC) from Malvern. ITC has become an essential technique in drug discovery and development and the new system is designed to deliver the enhanced functionality and robust performance now required. Its guided workflows with embedded help videos and advanced data analysis software make the system ideal for generating high quality data within a multi¬user environment.
This new biopharmaceutical applications lab in San Diego adds to the list of Malvern applications laboratories in all major territories around the world, underpinning Malvern’s commitment to supporting customers in all industries and all geographies.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Drug Combo Prevents Stroke, Shows Promise for ClinicNews
Taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days following a TIAREAD MORE
Vaccine to One Hemorrhagic Virus Could Protect Against OthersNews
Scientists report that antibodies made in response to a vaccine against one hemorrhagic fever virus—Junin—can successfully disarm one of its cousins, Machupo, for which there’s currently no vaccine.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018